| SEQ_NO | 1 | Date of announcement | 2024/10/24 | Time of announcement | 23:33:33 |
| Subject | Announcement that the company’s Board of Directors has resolved to acquisition of securities |
||||
| Date of events | 2024/10/24 | To which item it meets | paragraph 20 | ||
| Statement | 1.Name of the securities: Oneness Biotech Co., Ltd. 2.Trading date:2024/10/24 3.Amount, unit price, and total monetary amount of the transaction: Volume:7,100,000shares~8,000,000shares Unit Price:NT$125~NT$140 Total monetray amount:Within the quota of NT$1,000,000,000 4.Gain (or loss) through disposal (not applicable in case of acquisition of securities):NA 5.Relationship with the underlying company of the trade:Associates 6.Current cumulative amount held, monetary value, and shareholding percentage of cumulative holdings of the securities being traded (including the current trade), and status of any restriction of rights (e.g., pledges): Cumulative amount held: Cumulative holdings:101,043,446shares~101,943,446shares Cumulative holding amount:NT$3,620,258 thousand~NT$3,626,258 thousand Cumulative shareholding ratio:21.16%~21.35% Status of any restriction of rights:None 7.Current ratio of securities investment (including the current trade) to the total assets and equity attributable to owners of parent as shown in the most recent financial statement and working capital as shown in the most recent financial statement as of the present, as listed in the Regulations Governing the Acquisition and Disposal of Assets by Public Companies: Ratio to total assets: Proportion of total assets:82.81%~82.86% Proportion of shareholders’ equity:85.42%~85.47% Working capital:NT$1,645,566 thousand 8.Concrete purpose of the acquisition or disposal: The company is optimistic about Oneness Biotech Co., Ltd.’s high growth potential in revenue and profitability. 9.Whether the directors expressed any objection to the current transaction:None. 10.Whether the counterparty of the current transaction is a related party:Yes 11.Trading counterparty and its relationship to the Company: Trading counterparty:Diamond Biofund Inc. Relationship to the Company:Associates 12.Date of the board of directors’ resolution:2024/10/24 13.Date of ratification by supervisors or approval by the audit committee:2024/10/24 14.Any other matters that need to be specified:None. |
||||
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.